Onderneming Respirerx Pharmaceuticals Inc Other OTC
Aandelen
US2205243007
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22-03-13 |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22-03-13 |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 15-10-14 |
David Dickason
PRN | Corporate Officer/Principal | - | 15-09-20 |
Marc M. Radin
AUD | Comptroller/Controller/Auditor | - | 01-10-13 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22-03-13 |
Director/Board Member | - | 22-03-23 | |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22-03-13 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 365 418 647 | 341 184 734 ( 93,37 %) | 0 | 93,37 % |
Aandeel B | 0 | 37 500 | 0 | 0 |
Bedrijfsgegevens
RespireRx Pharmaceuticals, Inc.
126 Valley Road Suite C
07452, Glen Rock
+201 444 4947
http://www.respirerx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |
- Beurs
- Aandelen
- Koers RSPI
- Koers
- Onderneming Respirerx Pharmaceuticals Inc